These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 14675083)

  • 1. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
    J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
    Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
    Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
    Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
    J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
    Mouret P
    Hamostaseologie; 2002 Aug; 22(3):21-4. PubMed ID: 12215757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
    Eriksson BI; Ogren M; Eriksson UG; Kälebo P; Ahnfelt L; Björkström S; Sjöstedt A; Folestad A; Arfwidsson AC; Elvander CS; Frison L
    Thromb Res; 2002 Mar; 105(5):371-8. PubMed ID: 12062537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
    Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ximelagatran in orthopaedic surgery.
    Eriksson B
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():10-7. PubMed ID: 15812199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
    Eriksson BI
    Thromb Res; 2003 Jul; 109 Suppl 1():S23-9. PubMed ID: 12818631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
    Francis CW; Davidson BL; Berkowitz SD; Lotke PA; Ginsberg JS; Lieberman JR; Webster AK; Whipple JP; Peters GR; Colwell CW
    Ann Intern Med; 2002 Oct; 137(8):648-55. PubMed ID: 12379064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
    Agnelli G; Haas S; Ginsberg JS; Krueger KA; Dmitrienko A; Brandt JT
    J Thromb Haemost; 2007 Apr; 5(4):746-53. PubMed ID: 17408408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety.
    Dahl OE; Eriksson BI; Agnelli G; Cohen AT; Mouret P; Rosencher N; Panfilov S; Bylock A; Andersson M
    Clin Drug Investig; 2005; 25(1):65-77. PubMed ID: 17523747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
    Colwell CW; Berkowitz SD; Lieberman JR; Comp PC; Ginsberg JS; Paiement G; McElhattan J; Roth AW; Francis CW;
    J Bone Joint Surg Am; 2005 Oct; 87(10):2169-77. PubMed ID: 16203879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
    Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
    Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.